Blog

2024 Equity in Access Research Program Grantees of The Leukemia and Lymphoma Society

Photo taken from The Leukemia and Lymphoma Society/X

Jul 13, 2024, 05:22

2024 Equity in Access Research Program Grantees of The Leukemia and Lymphoma Society

The Leukemia and Lymphoma Society shared on X:

“Let’s applaud our 2024 Equity in Access Research Program Grantees! We’ve awarded nearly $6.5M to address barriers to blood cancer treatment & care that may lead to better health outcomes – supported by Royalty Pharma & Astra Zeneca. Discover more about our grantees & their work.”

Source: The Leukemia and Lymphoma Society/X

AstraZeneca blood cancer care blood cancer treatment cancer cancer care barriers Cancer Equity cancer research funding cancer research grantees Cancer Treatment Access Equity in Access Research Program health outcomes Leukemia and Lymphoma Society OncoDaily Oncology Royalty Pharma

Senator Edward Markey in Response to OncoDaily About Pediatric Cancer Funding

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity